Wedbush maintained Sangamo BioSciences (NASDAQ: SGMO ) with an Outperform rating and raised the price target from $10.00 to $13.00. Wedbush said, "Sangamo presented immunologic results supporting previous observations about the functionality and durability of SB-728-T modified T-cells at the 20th Conference on Retroviruses and Opportunistic Infections (CROI). … We